back to overview

news

MTIP has sucessfully exited Blueprint Genetics

January 22, 2020 + Jessica Di Palo
5 Min read

Quest Diagnostics Acquires Blueprint Genetics to Broaden Access to Actionable Insights for Genetic and Rare Diseases

MTIP exits Blueprint genetics

MTIP has successfully exited Blueprint Genetics to Quest Diagnostics. Together, Quest Diagnostics, the world’s leading provider of diagnostic information services, and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. Financial terms of the transaction were not disclosed.

Basel, Switzerland – January 22, 2020

Blueprint Genetics is expected to continue to operate largely independently from its base laboratory in Helsinki, Finland, and a presence in other countries. The acquisition provides a platform for Blueprint Genetics to leverage Quest’s capabilities in next generation sequencing and national infrastructure serving half the health systems and physicians in the United States.

“The great challenge with genetic testing is generating quality, actionable and broadly accessible insights from vast quantities of sequenced genetic data,” said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics. “Blueprint Genetics has developed a proven model for delivering highly specialized genetic insights that we believe we can scale to serve new patient populations with unmet clinical needs. The addition of Blueprint Genetics strengthens and extends the Quest value proposition in genetics, delivering on our Accelerate growth strategy and vision of a healthier world.”

Founded in 2012, Blueprint Genetics grew rapidly, and now serves customers in over 70 countries. Blueprint Genetics has increased its focus and presence in the United States through a recently established hub facility in Seattle, Washington. The company’s growth is based largely on proprietary guideline-supported methods of gene variant interpretation of data generated from next generation sequencing, backed by high-touch consultative service. The company provides 3,900 targeted single gene and over 200 panel tests spanning 14 medical specialties. Gene variant interpretation involves identifying associations between gene variants and disease or treatment response.

Through its Advanced Diagnostics offerings, Quest specializes in combining state-of-the-art technologies, such as next generation sequencing, with higher-order interpretative expertise and digital customer enablement. Blueprint Genetics brings to Quest high-touch service in variant interpretation and reporting and associated sequencing and bioinformatics, which complement and extend its existing genetics leadership.

“As the leader in Advanced Diagnostics, Quest Diagnostics understands that robust bioinformatics and consultative expertise are essential to fast, accurate and cost-efficient data interpretation,” said Carrie Eglinton Manner, Senior Vice President, Advanced Diagnostics, Quest Diagnostics. “Blueprint Genetics brings to Quest a proven platform in specialty genetics — especially gene variant interpretation and reporting — that powerfully differentiates our Advanced Diagnostics offering.”

Over time, the acquisition is expected to yield new capabilities to serve providers specializing in rare disease and neurology, particularly pediatric and academic hospitals. The two organizations also envision that members of the Quest Diagnostics Global Diagnostic Network and its pharmaceutical and in vitro diagnostic collaborators will benefit from Blueprint Genetics’ capabilities.

“Blueprint Genetics prides itself on resolving the most challenging genetic and rare disease cases to improve patient outcomes,” said Tommi Lehtonen, who has agreed to continue to lead the company, reporting to Ms. Eglinton Manner. “Teaming up with Quest will allow us to extend our capabilities in the United States as well as in Canada and other countries where we already have strong and growing client relationships. While we considered joining forces with several organizations, Quest’s genetics leadership, national infrastructure and strong cultural fit made it the perfect partner from which to extend our reach to new providers and patients.”

Genetic testing can aid in diagnosing many rare diseases as well as identifying future risk of and treatment for certain cancers and other conditions. According to the National Institutes of Health, as many as 7,000 rare diseases exist and as many as 30 million Americans have a rare disease.

David Germonpré, Partner at MTIP added “The successful exit of Blueprint Genetics after only 2.5 years reflects the capacity of MTIP to carefully select winners in the fast growing Healthtech space. From our board position we implemented our active investment approach to scale the company’s annual revenues with a 7x increase since investment, and we are delighted to see that Blueprint Genetics is now on track to continue its phenomenal growth path with the support of a new owner like Quest Diagnostics.”

 

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 46,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

About Blueprint Genetics

Blueprint Genetics is one of the fastest growing genetic diagnostics businesses globally in the field of clinical genetic testing of rare inherited diseases. The company is based in Helsinki and Seattle, with a customer base spanning over 70 countries. www.blueprintgenetics.com.

 

Share the Article

blog

SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right

news

MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round

news

MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia

blog

Private Equity 101: Part one – Glossary

Are you new to the healthtech space?

blog

Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey

blog

Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations

news

MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II

blog

How to pitch to a healthtech Investor

Blog Pitching

news

MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health

news

MTIP scored fantastic grades in the UNPRI assessment report of 2020

UNPRI Report grades 2020

press

4 Health VCs Share Their Business Priorities and What is Next

Interview Techtour

news

MTIP invests in Trialbee

New investment in Trialbee

news

TytoCare closes $50 million round as the demand for telehealth accelerates

TytoCare closes new round

news

The digital healthtech sector is expanding – and so are we!

Two new empolyees start in April

news

MTIP has sucessfully exited Blueprint Genetics

Blueprint exit January 2020

news

New MTIP investment in Oviva

New investment in Oviva

press

Whitepaper: A positive prognosis for the future of healthtech

Our first Whitepaper

press

Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch

Elite Summit 2019

news

MTIP Healthcare Clinic 2019

Healthcare clinic 2019

New MTIP investment in Cynerio

New investment in Cynerio

news

MTIP invests in Lumeon Ltd.

New investment in Lumeon

Magenverkleinerung mit der Handnähmaschine

Nitinotes news paper article

news

New MTIP investment in Quanta Dialysis Technologies

New investment in Quanta